Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis

References

• Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929–361Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929–36
   PubMed Web of Science ®Google Scholar
• Center JR, Nguyen TV, Schneider D. et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878–822Center JR, Nguyen TV, Schneider D. et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878–82
   PubMed Web of Science ®Google Scholar
• Melton 3rd LJ, Atkinson EJ, O’Fallon WM. et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227–333Melton 3rd LJ, Atkinson EJ, O’Fallon WM. et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227–33
   PubMed Web of Science ®Google Scholar
• Seeman E, Delmas PD. Bone quality – the material and structural basis of bone strength and fragility. N Engl J Med 2006;354: 2250–614Seeman E, Delmas PD. Bone quality – the material and structural basis of bone strength and fragility. N Engl J Med 2006;354: 2250–61
   PubMed Web of Science ®Google Scholar
• Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018–265Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018–26
   PubMed Web of Science ®Google Scholar
• Delmas PD, Recker RR, Chesnut 3rd CH. et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792–86Delmas PD, Recker RR, Chesnut 3rd CH. et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792–8
   PubMed Web of Science ®Google Scholar
• Eastell R, Barton I, Hannon RA. et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051–67Eastell R, Barton I, Hannon RA. et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051–6
   PubMed Web of Science ®Google Scholar
• Briot K, Roux C. What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring? Best Pract Res Clin Rheumatol. 2005;19:951–648Briot K, Roux C. What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring? Best Pract Res Clin Rheumatol. 2005;19:951–64
   PubMed Web of Science ®Google Scholar
• Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 2004;4:50–639Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 2004;4:50–63
   PubMedGoogle Scholar
• Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005;17:462–610Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005;17:462–6
   PubMed Web of Science ®Google Scholar
• Palomba S, Numis FG, Mossetti G. et al. Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes. Clin Endocrinol (Oxf) 2003;58:365–7111Palomba S, Numis FG, Mossetti G. et al. Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes. Clin Endocrinol (Oxf) 2003;58:365–71
   PubMed Web of Science ®Google Scholar
• Marc J, Prezelj J, Komel R. et al. VDR genotype and response to etidronate therapy in late post-menopausal women. Osteoporos Int 1999;10:303–612Marc J, Prezelj J, Komel R. et al. VDR genotype and response to etidronate therapy in late post-menopausal women. Osteoporos Int 1999;10:303–6
   PubMed Web of Science ®Google Scholar
• Arko B, Prezelj J, Komel R. et al. No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis. J Steroid Biochem Mol Biol 2002;81:147–5213Arko B, Prezelj J, Komel R. et al. No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis. J Steroid Biochem Mol Biol 2002;81:147–52
   PubMed Web of Science ®Google Scholar
• Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643–5814Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643–58
   PubMedGoogle Scholar
• Luckman SP, Coxon FP, Ebetino FH. et al. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure–activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668–7815Luckman SP, Coxon FP, Ebetino FH. et al. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure–activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668–78
   PubMed Web of Science ®Google Scholar
• Benford HL, Frith JC, Auriola S. et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131–4016Benford HL, Frith JC, Auriola S. et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131–40
   PubMed Web of Science ®Google Scholar
• Van Beek E, Pieterman E, Cohen L. et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen- containing bisphosphonates. Biochem Biophys Res Commun 1999; 264: 108–1117Van Beek E, Pieterman E, Cohen L. et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen- containing bisphosphonates. Biochem Biophys Res Commun 1999; 264: 108–11
   PubMed Web of Science ®Google Scholar
• Ferlazzo V, Sferrazza C, Caccamo N. et al. In vitro effects of aminobisphosphonates on Vgamma9Vdelta2 T cell activation and differentiation. Int J Immunopathol Pharmacol 2006; 19:309–1718Ferlazzo V, Sferrazza C, Caccamo N. et al. In vitro effects of aminobisphosphonates on Vgamma9Vdelta2 T cell activation and differentiation. Int J Immunopathol Pharmacol 2006; 19:309–17
   PubMed Web of Science ®Google Scholar
• Carbonell Sala S, Masi L, Marini F. et al. Genetics and pharmacogenetics of osteoporosis. J Endocrinol Invest 2005;28:2–719Carbonell Sala S, Masi L, Marini F. et al. Genetics and pharmacogenetics of osteoporosis. J Endocrinol Invest 2005;28:2–7
   PubMedGoogle Scholar
• Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006;6:307–1220Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006;6:307–12
   PubMed Web of Science ®Google Scholar
• Carbonell Sala S, Falchetti A, Martineti V. et al. Intron 1 polymorphism (A/C) of FDPS gene: a new genetic marker for N-BPs therapy response? Proceeding of The ASBMR XXVII Annual Meeting, Nashville, USA, 2005, Abstract SA121. J Bone Miner Res 2005;20:1–51221Carbonell Sala S, Falchetti A, Martineti V. et al. Intron 1 polymorphism (A/C) of FDPS gene: a new genetic marker for N-BPs therapy response? Proceeding of The ASBMR XXVII Annual Meeting, Nashville, USA, 2005, Abstract SA121. J Bone Miner Res 2005;20:1–512
   Google Scholar
• Haga H, Yamada R, Ohnishi Y. et al. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism. J Hum Genet 2002; 47:605–1022Haga H, Yamada R, Ohnishi Y. et al. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism. J Hum Genet 2002; 47:605–10
   PubMed Web of Science ®Google Scholar
• Bagger YZ, Tankó LB, Alexandersen P. et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728–3523Bagger YZ, Tankó LB, Alexandersen P. et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728–35
   PubMed Web of Science ®Google Scholar
• Christgau S, Rosenquist C, Alexandersen P. et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 1998; 44:2290–30024Christgau S, Rosenquist C, Alexandersen P. et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 1998; 44:2290–300
   PubMed Web of Science ®Google Scholar
• Rosenquist C, Qvist P, Bjarnason N. et al. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 1995;41:1439–4525Rosenquist C, Qvist P, Bjarnason N. et al. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 1995;41:1439–45
   PubMed Web of Science ®Google Scholar
• McClung M, Clemmesen B, Daifotis A. et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998; 128:253–6126McClung M, Clemmesen B, Daifotis A. et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998; 128:253–61
   Google Scholar
• Eastell R, Hannon RA, Garnero P. et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 2007;22:1656–6027Eastell R, Hannon RA, Garnero P. et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 2007;22:1656–60
   PubMed Web of Science ®Google Scholar
• Calis KA, Pucino F. Zoledronic acid and secondary prevention of fractures. N Engl J Med 2007;357:1861–228Calis KA, Pucino F. Zoledronic acid and secondary prevention of fractures. N Engl J Med 2007;357:1861–2
   PubMed Web of Science ®Google Scholar
• Farrugia MC, Summerlin DJ, Krowiak E. et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006;116:115–2029Farrugia MC, Summerlin DJ, Krowiak E. et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006;116:115–20
   PubMed Web of Science ®Google Scholar
• Marx RE, Sawatari Y, Fortin M. et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567–7530Marx RE, Sawatari Y, Fortin M. et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567–75
   PubMed Web of Science ®Google Scholar
• Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895–631Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895–6
   PubMed Web of Science ®Google Scholar
• Saltman LH, Javed A, Ribadeneyra J. et al. Organization of transcriptional regulatory machinery in osteoclast nuclei: compartmentalization of runx1. J Cell Physiol 2005;204:871–8032Saltman LH, Javed A, Ribadeneyra J. et al. Organization of transcriptional regulatory machinery in osteoclast nuclei: compartmentalization of runx1. J Cell Physiol 2005;204:871–80
   PubMed Web of Science ®Google Scholar
• Levy ME, Parker Ra, Ferrell RE. et al. Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women. Maturitas 2007;57:247–5233Levy ME, Parker Ra, Ferrell RE. et al. Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women. Maturitas 2007;57:247–52
   PubMed Web of Science ®Google Scholar